Physician profile
Divya Salhan
NPI 1780933531
$5,055.66
in general payments reported to CMS, 2019-2025
21 companies · $928 in 2025
The $928 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $354 · 2022: $1,620 · 2023: $1,041 · 2024: $1,113 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011 · Education: $71.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,010.71 |
| Education | $71.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $930.53 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Olympus Corporation of The Americas | $785.55 | 2022 | |
| Glaxosmithkline, LLC. | $558.54 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Inspire Medical Systems, INC. | $440.08 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.07 | 2021-2025 | Ofev |
| Harmony Biosciences LLC | $352.46 | 2023-2025 | Wakix |
| Genzyme Corporation | $281.36 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $263.59 | 2021-2024 | Glassia |
| Mylan Specialty L.P. | $230.89 | 2021-2024 | Yupelri |
| Grifols USA, LLC | $156.31 | 2021-2024 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $96.86 | 2021-2022 | |
| Philips North America LLC | $86.07 | 2022-2023 | |
| Baxter Healthcare | $80.50 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System, Hillrom - Monarch Airway Clearance System |
| Regeneron Healthcare Solutions, INC. | $75.17 | 2024-2025 | Dupixent |
| Avadel Cns Pharmaceuticals, LLC | $63.00 | 2024-2025 | Lumryz |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $60.47 | 2023-2024 | Smartvest |
| Insmed, INC. | $57.71 | 2022-2023 | Arikayce |
| United Therapeutics Corporation | $34.82 | 2022-2023 | Tyvaso |
| Advanced Respiratory, INC | $31.28 | 2021 | |
| Axsome Therapeutics, INC. | $24.04 | 2024 | Sunosi |
| Idorsia Pharmaceuticals US INC | $14.36 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Salhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.